I rate Cytek Biosciences (NASDAQ: CTKB ) with a Buy rating. I think the net losses that the company has reported since mid-2022 do not correspond with the 79.82% plunge in its stock price. Cytek hasDaniel Mellado is an economist from Carabobo University with a Master's Degree in Statistics from Simon Bolivar University, both obtained in Venezuela.Daniel worked analyzing the agricultural commodity market and the financial investment portfolio for an agribusiness group. Then, he managed two teams, one in trad ...

Core Insights - Cytek Biosciences is committed to advancing cell analysis through its patented Full Spectrum Profiling™ (FSP) technology, which will be showcased at key industry events such as CYTO 2025 and IMMUNOLOGY2025 [1][2][5] Company Overview - Cytek Biosciences, Inc. (Nasdaq: CTKB) is a leading company in cell analysis solutions, focusing on high-resolution, high-content, and high-sensitivity tools [6][7] - The company’s FSP technology enhances multiplexing capabilities with precision and sensitivity, positioning it as a pioneer in spectral flow cytometry [6][2] Industry Events - At IMMUNOLOGY2025, Cytek will present its complete cell analysis solutions, including instruments, reagents, and software, aimed at advancing research and discovery [3][4] - The company will also host a workshop on in-depth characterization of mouse immune responses during the event [4] - CYTO 2025 will feature Cytek as a Platinum sponsor, where it will showcase technology designed to accelerate scientific discovery [4][5] Strategic Goals - Cytek aims to make flow cytometry technology more accessible and scalable, unlocking new opportunities in high-growth areas such as immunology, oncology, and cell therapy [2][5] - The company emphasizes its commitment to delivering innovative and flexible solutions to empower researchers and accelerate breakthroughs in scientific advancement [5]

He leads the investing group Beyond the Wall Investing with features that include: a fundamentals-based portfolio, weekly analysis on insights from institutional investors, regular alerts for short-term trade ideas based on technical signals, ticker feedback by request from readers, and community chat. Learn more With just one subscription to Beyond the Wall Investing , you can save thousands of dollars a year on equity research reports from banks. You'll keep your finger on the pulse and have access to the ...

FREMONT, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the “Investors” section of th ...

Core Viewpoint - Cytek Biosciences has launched the Cytek® Muse® Micro cell analyzer, a next-generation instrument that enhances flow cytometry capabilities while being affordable and user-friendly, targeting various markets including cell and gene therapy and drug discovery [1][2][3] Product Features - The Muse Micro cell analyzer builds on the original Muse system, which was the most compact flow cytometer when introduced in 2013, and has a significant installed base globally [2] - It features a 488 nm blue laser, five parameters including forward and side scatter, and three fluorescent channels, making routine assays faster and more accessible [2][5] - The compact design measures 8 in x 10 in (20 cm x 25 cm) and utilizes advanced microcapillary technology for precise cell counts without the need for calibration beads [5] Market Opportunities - The Muse Micro system aims to make advanced cellular instrumentation accessible to smaller labs and resource-limited facilities, thus expanding Cytek's market reach [3] - It is designed for diverse testing environments across industries such as drug discovery, biopharma, and water quality testing, making it suitable for both academic and industrial laboratories [3][4] Company Overview - Cytek Biosciences is a leading cell analysis solutions company known for its Full Spectrum Profiling™ (FSP®) technology, which enhances multiplexing with precision and sensitivity [4] - The company offers a comprehensive suite of solutions including core FSP instruments, reagent preparation systems, and imaging products under various brands [4]

Cytek Biosciences (CTKB) Q4 2024 Earnings Call February 28, 2025 02:21 AM ET Company Participants Paul Goodson - Head of IRWenbin Jiang - President, CEO & Chairman of the BoardWilliam McCombe - Chief Financial OfficerNoah Lewis - Equity Research AssociateChad Wiatrowski - VP - Equity ResearchHarrison Parsons - Research Associate Conference Call Participants David Westenberg - Managing Director & Senior Research AnalystNone - AnalystMatt Sykes - Analyst Operator Thank you for standing by and good day everyon ...

Company Performance - Cytek Biosciences, Inc. reported quarterly earnings of $0.07 per share, exceeding the Zacks Consensus Estimate of $0.06 per share, and matching the earnings from a year ago [1] - The company posted revenues of $57.48 million for the quarter ended December 2024, which was 9.49% below the Zacks Consensus Estimate and a decrease from $58.23 million year-over-year [2] - Over the last four quarters, Cytek has surpassed consensus EPS estimates two times and topped consensus revenue estimates twice [2] Stock Movement and Outlook - Cytek Biosciences shares have declined approximately 23% since the beginning of the year, contrasting with the S&P 500's gain of 1.3% [3] - The sustainability of the stock's price movement will largely depend on management's commentary during the earnings call [3] - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $48.02 million, with a breakeven estimate on revenues of $222.35 million for the current fiscal year [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Cytek belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Cytek's stock performance [5][6]

FORM 10-K ____________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number 001-40632 ____________________________________ Table of Contents Washington, D.C. 20549 ___________________________________ ...

Financial Results Announcement - Cytek Biosciences, Inc. announced preliminary unaudited revenue for Q4 2024 and full year ended December 31, 2024[4]. - The press release regarding the financial results was issued on January 15, 2025[4]. - The report does not include detailed financial figures or performance metrics in the provided content[4]. - The financial results are not deemed "filed" under the Securities Exchange Act of 1934[5]. Company Information - The company is listed on the Nasdaq Global Select Market under the symbol CTKB[2]. - The company is not classified as an emerging growth company[3]. - The filing does not include any new or revised financial accounting standards compliance[3]. - The report includes an interactive data file as part of the exhibits[7]. - The report was signed by Wenbin Jiang, President and CEO of Cytek Biosciences, Inc.[11]. - The address of the company's principal executive offices is 47215 Lakeview Boulevard, Fremont, California 94538[1].

Core Insights - Cytek Biosciences reported a total revenue of $57.5 million for Q4 2024, a slight decrease of 1.3% from $58.2 million in Q4 2023, but a 1.4% increase on a non-GAAP constant currency basis [4][11] - The company achieved a gross profit of $33.7 million in Q4 2024, reflecting a 1.8% increase from $33.0 million in Q4 2023, with a gross margin improvement to 59% from 57% [5][12] - For the full year 2024, total revenue reached $200.5 million, marking a 3.9% increase over 2023, with adjusted EBITDA rising significantly by 77% to $22.4 million [11][17] Financial Performance - Q4 2024 operating expenses were $30.7 million, with a non-recurring benefit of $2.6 million from a license and royalty settlement adjustment; excluding this, non-GAAP operating expenses remained unchanged from Q4 2023 [6][8] - The net income for Q4 2024 was reported at $9.6 million, which included non-recurring benefits totaling $8.8 million; without these, non-GAAP net income would have been $2.9 million, down from $5.5 million in Q4 2023 [9][10] - For the full year 2024, the net loss was $6.0 million, an improvement from a net loss of $12.1 million in 2023, with total adjusted EBITDA for the year at $22.4 million compared to $12.6 million in 2023 [16][17] Operational Highlights - The installed base of Cytek instruments expanded to 3,034, with 667 new instruments placed during 2024 [7] - A new manufacturing facility was opened in Singapore to enhance capacity and global supply flexibility [17] - The company repurchased 3,971,624 shares at a cost of approximately $21.6 million and announced a new stock repurchase program for up to $50 million in 2025 [7][17] Future Outlook - Cytek expects total revenue for 2025 to be between $204 million and $212 million, indicating a growth of 2% to 6% over 2024 [19]